Morisky Widget Medication Adherence Protocol for OUD Patients On Medication Assisted Therapy

IBM Watson research IN 2019 reported that patients with opioid use disorders (OUD) struggled to take oral MAT on a regular schedule. A national cohort of > 22,000 OUD patients, had < 50% adherence to their MAT. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165853/)

According to Pennsylvania’s Health Department, MAT must be provided for significantly longer than the traditional 90 days to maintain positive outcomes. For those who use methadone, a one-year protocol is considered the minimum (https://www.paauditor.gov/Media/Default/Reports/RPT_Fentanyl_101619_FINAL.pdf)

According to the 2016 Surgeon General’s Report on Alcohol, Drugs, and Health, “MAT for patients with OUD must be delivered for an adequate duration in order to be effective. Patients who receive MAT for fewer than 90 days have not shown improved outcomes”. One study suggested that individuals who receive MAT for fewer than 3 years are more likely to relapse than those who are in treatment for 3 or more years. https://www.ncbi.nlm.nih.gov/books/NBK424857/pdf/Bookshelf_NBK424857.pdf

MMAS Research LLC wishes to provide any MAT provider with the Morisky Widget Medication Adherence Protocol which not only measures the precise level of adherence to buprenorphine and methadone, the Widget identifies why the patient is not taking their opioid medication replacement treatment, providing tailored and targeted interventions, Please contact us if you are interested in a live demonstration,